• Journal of Plant Biotechnology
• /
• v.29 no.1
• /
• pp.59-62
• /
• 2002

Samyang Genex succeeded in commercialization of anticancer agent-paclitaxel by plant cell culture technology. The core technology of Samyang Genex relating paclitaxel production includes cell line development, cell line preservation, cell culture, scale-up technology, and purification technology. On the basis of the research, Samyang Genex built the factory operated by CGMP (current good manufacturing practice). The paclitaxel-Genexol$^{TM}$-is commercially available in Korea, and it will be launched to world market including USA after approval of US FDA.

• Proceedings of the Korean Society of Plant Biotechnology Conference
• /
• 2002.04a
• /
• pp.27-31
• /
• 2002

Samyang Genex succeeded in commercialization of anticancer agent-paclitaxel by plant cell culture technology. The core technology of Samyang Genex relating paclitaxel production includes cell line development, cell line preservation, cell culture, scale-up technology, and purification technology. On the basis of the research, Samyang Genex built the factory operated by CGMP (current good manufacturing practice). The $paclitaxel-Genexol^{TM}$ is commercially available in Korea, and it will be launched to world market including USA after approval US FDA.

• Proceedings of the Korean Society of Plant Biotechnology Conference
• /
• 2002.04b
• /
• pp.27-31
• /
• 2002

Samyang Genex succeeded in commercialization of anticancer agent-paclitaxel by plant cell culture technology. The core technology of Samyang Genex relating paclitaxel production includes cell line development, cell line preservation, cell culture, scale-up technology, and purification technology. On the basis of the research, Samyang Genex built the factory operated by CGMP (current good manufacturing practice). The $paclitaxel-Cenexol^{TH}-is$ commercially available in Korea, and it will be launched to world market including USA after approval of US FDA.